Skip to main content

View full-text article in PMC

. 2014 Dec;55(12):2509–2520. doi: 10.1194/jlr.M051631

TABLE 2.

Total mass and % lipid and protein composition (wt/wt) of HDL subpopulations from apoA-I-deficient patients and control subjects

Group	HDL2b	HDL2a	HDL3a	HDL3b	HDL3c
Total mass (mg/dl)
Control	83.6 ± 33.2	94.5 ± 12.3	79.6 ± 14.6	35.3 ± 7.1	15.1 ± 3.4
Heterozygotes	36.3 ± 8.0^b	56.5 ± 19.0^a	66.7 ± 23.0	32.0 ± 12.0	12.8 ± 4.0
Homozygotes	23.0 (23.5, 22.6)^b	8.5 (8.1, 8.6)^a	8.2 (7.4, 9.0)^a	6.5 (5.8, 7.2)^a	3.1 (2.8, 3.4)^a
CE, wt%
Control	28.5 ± 5.0	23.6 ± 3.7	22.2 ± 4.1	18.8 ± 3.2	16.6 ± 2.4
Heterozygotes	31.4 ± 2.6	20.1 ± 1.3^c	18.9 ± 0.9	17.3 ± 2.3	12.4 ± 3.0^b
Homozygotes	25.7 (24.0, 27.4)	19.1 (18.3, 20.4)	16.8 (17.0, 16.6)	8.7 (8.9, 8.6)^a	13.9 (17.15, 10.8)
TG, wt%
Control	5.6 ± 2.3	3.8 ± 1.5	3.4 ± 1.3	3.1 ± 1.7	3.4 ± 1.9
Heterozygotes	7.2 ± 1.8	4.9 ± 1.0	4.7 ± 1.2^c	4.2 ± 1.8	3.1 ± 0.9
Homozygotes	7.2 (5.5, 8.9)	6.5 (6.9, 6.0)^c	6.5 (8.2, 4.8)^c	3.0 (3.0, 3.0)	2.9 (4.0, 1.7)
GP, wt%
Control	31.5 ± 5.1	29.0 ± 4.5	28.1 ± 3.5	26.1 ± 2.6	20.0 ± 2.6
Heterozygotes	21.9 ± 3.6^b	27.8 ± 2.7	25.7 ± 1.7	20.9 ± 1.9^a	15.3 ± 0.7^a
Homozygotes	24.1 (26.7, 21.6)	25.0 (25.9, 24.3)	20.5 (20.8, 20.0)^c	17.0 (17.4, 16.5)^a	12.3 (13.8, 12.0)^a
FC, wt%
Control	6.5 ± 0.7	3.9 ± 0.5	2.9 ± 0.3	2.5 ± 0.3	2.0 ± 0.4
Heterozygotes	8.7 ± 1.1^a	3.7 ± 0.1	2.9 ± 0.2	2.7 ± 0.3	2.8 ± 0.7^c
Homozygotes	12.3 (13.9, 10.6)^a	8.3 (9.9, 6.7)^a	4.6 (5.4, 3.9)^a	5.9 (7.6, 4.3)^a	5.7 (5.3, 6.1)^a
Total protein, wt%
Control	28.1 ± 4.6	39.5 ± 5.2	43.5 ± 4.5	49.1 ± 5.6	58.3 ± 4.8
Heterozygotes	30.8 ± 1.2	43.4 ± 2.4	47.7 ± 2.4	54.9 ± 3.0^c	66.4 ± 3.0^b
Homozygotes	30.6 (29.8, 31.5)	40.9 (39.0, 42.8)	51.5 (48.6, 54.6)^c	59.0 (63.1, 67.0)^b	64.4 (59.7, 69.3)

Data obtained in two heterozygotes are shown as means (individual values).

^a

P < 0.001; versus controls.

^b

P < 0.01; versus controls.

^c

P < 0.05; versus controls.